CAT 5571

Drug Profile

CAT 5571

Alternative Names: CAT-5571

Latest Information Update: 23 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Antifibrotics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 17 Nov 2016 Catabasis Pharmaceuticals plans a phase I trial for Cystic fibrosis
  • 27 Oct 2016 Positive pharmacodynamics data from preclinical study released by Catabasis Pharmaceuticals
  • 20 Oct 2016 Preclinical trials in Cystic fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top